Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy (Q34119511)

31 July 2017

Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy (English)

1 reference

31 July 2017

1 reference

Koki AT

1

1 reference

31 July 2017

Leahy KM

series ordinal

2

1 reference

31 July 2017

Masferrer JL

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

1 reference

31 July 2017

8

1 reference

31 July 2017

10

1 reference

31 July 2017

1623-1638

1 reference

Regulation of prostaglandin synthase-1 and prostaglandin synthase-2.

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Pharmacological analysis of cyclooxygenase-1 in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Prostaglandins in breast cancer: relationship to disease stage and hormone status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Lessons from hereditary colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Nonsteroidal antiinflammatory drugs and colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Nonsteroidal antiinflammatory drugs and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

NSAID use and decreased risk of gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Inflammatory PGE2 production is maintained during hypoxia in rheumatoid synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Aspirin-like molecules that covalently inactivate cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Generation of mutagens during arachidonic acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Xenobiotic metabolism by prostaglandin H synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Prostaglandin synthetase dependent activation of 7,8-dihydro-7,8-dihydroxy-benzo(a)pyrene to mutagenic derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Prostaglandin endoperoxide synthetase-mediated metabolism of carcinogenic aromatic amines and their binding to DNA and protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Importance of apoptosis in the histopathology of drug related lesions in the large intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

Aspirin and the Risk of Colorectal Cancer in Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.10.1623

10.1517/13543784.8.10.1623

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference